Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study

BACKGROUND: Regdanvimab has decreased the time to clinical recovery from coronavirus disease 2019 (COVID-19) and lowered the rate of oxygen therapy according to the results from phase 2/3 randomized controlled trial. More information is needed about the effects and safety of regdanvimab. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Susin, Je, Nam Kyung, Kim, Dong Wan, Park, Miran, Heo, Jeonghun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980364/
https://www.ncbi.nlm.nih.gov/pubmed/35380027
http://dx.doi.org/10.3346/jkms.2022.37.e102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980364/
https://www.ncbi.nlm.nih.gov/pubmed/35380027
http://dx.doi.org/10.3346/jkms.2022.37.e102

Ejemplares similares